Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Pharmacokinetic and therapeutic equivalence of Zelapar and Eldepryl

Oct. 27, 1998

New serotonergic agents in development at ADIR for CNS disorders

Oct. 27, 1998

Yamanouchi discloses 5-HT2C receptor agonists with high potency and selectivity

Oct. 27, 1998

Korean research institute develops new NMDA receptor antagonists

Oct. 27, 1998

Agents for schizophrenia from Yoshitomi typified by Y-36074

Oct. 27, 1998

Dainippon will initiate European development of antipsychotic drug candidate

Oct. 27, 1998

Sublingual apomorphine safe and effective in PD patients with motor fluctuations

Oct. 26, 1998

Transdermal selegiline as monotherapy in mild to moderate Parkinson's disease

Oct. 26, 1998

Transdermal D2 agonist therapy with N-0923 safe and effective in PD

Oct. 26, 1998

Metabasis Therapeutics seeks partner for development of anticonvulsant

Oct. 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.